Mereo BioPharma Group plc (MREO) P/S ratio
Only 2 fiscal years of P/S ratio are on record here for Mereo BioPharma Group plc (MREO); a history needs at least 3. Mereo BioPharma Group plc (MREO) trades at 87.5× its revenue per share for fiscal 2025. Figures as of 18 Nov 2026, 10:32 UTC, from Yahoo Finance.
Key facts
- P/S ratio today
- 87.5×
- P/S ratio, fiscal 2025
- 133.0×
- Fiscal years on record
- 22023–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/S ratio needs at least 3 fiscal years; 2 are on record here for Mereo BioPharma Group plc. Nothing is estimated to fill the gap. What is on record is in the table below.
Mereo BioPharma Group plc P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 87.5× | — | $0.27 | — | |
| 2025 | 133.0× | — | $0.42 | $0.00 | |
| 2024 | — | — | $3.50 | — | |
| 2023 | 30.5× | — | $2.31 | $0.08 | |
| 2022 | — | — | $0.75 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
Mereo BioPharma Group plc, figure by figure
- Mereo BioPharma Group plc market cap
- Mereo BioPharma Group plc revenue
- Mereo BioPharma Group plc earnings
- Mereo BioPharma Group plc earnings per share (EPS)
- Mereo BioPharma Group plc P/E ratio
- Mereo BioPharma Group plc P/B ratio
- Mereo BioPharma Group plc free cash flow
- Mereo BioPharma Group plc operating margin
- Mereo BioPharma Group plc dividend
- Mereo BioPharma Group plc shares outstanding
- Mereo BioPharma Group plc total debt
- Mereo BioPharma Group plc cash on hand
- Mereo BioPharma Group plc total assets
- Mereo BioPharma Group plc return on equity (ROE)
- Mereo BioPharma Group plc return on invested capital (ROIC)
Mereo BioPharma Group plc (MREO) overview: price, valuation and scorecard
Mereo BioPharma Group plc P/S ratio: questions and answers
What is Mereo BioPharma Group plc's P/S ratio?
Mereo BioPharma Group plc (MREO) trades at 87.5× its revenue per share for fiscal 2025.
How is Mereo BioPharma Group plc's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Mereo BioPharma Group plc it is on record here for 2 fiscal years, 2023 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Mereo BioPharma Group plc (MREO) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/MREO/ps-ratio
Underlying data: Yahoo Finance.